AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SRPT
  4. [8-K] Sarepta Therapeutics,, Inc. Reports Material Event

[8-K] Sarepta Therapeutics,, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock SRPT logo
Sarepta Therapeutics Inc

NASDAQ:SRPT

SRPT Rankings

#1502 Ranked by Market Cap
N/A Ranked by Dividends
#54 Top Gainer

SRPT Latest News

Jul 16, 2025
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Jun 30, 2025
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 15, 2025
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Jun 4, 2025
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
May 21, 2025
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

SRPT Stock Data

1.87B
93.93M
4.41%
92.37%
5.22%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE